Related Experiment Video

Updated: May 7, 2026

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer

R Ferraldeschi1, C Pezaro, V Karavasilis

  • 1Division of Cancer Therapeutics, Signal Transduction & Molecular Pharmacology and Clinical Pharmacology & Trials Team, Institute of Cancer Research, Sutton, SM25NG, United Kingdom. Roberta.ferraldeschi@icr.ac.uk

Annual Review of Medicine
|October 2, 2012
PubMed

Insights

Medical castration for advanced prostate cancer is common but resistance develops. New therapies targeting androgen receptor signaling, like abiraterone acetate and enzalutamide, offer hope for castration-resistant prostate cancer.

Area of Science:

  • Oncology
  • Urology
  • Endocrinology

Background:

  • Androgen deprivation therapy (castration) is the standard treatment for advanced prostate cancer.
  • Prostate cancer invariably progresses to a castration-resistant state despite initial treatment.
  • Understanding androgen receptor (AR) signaling is crucial for overcoming treatment resistance.

Purpose of the Study:

  • To review current concepts and challenges in targeting AR signaling in castration-resistant prostate cancer (CRPC).
  • To provide an overview of clinical trials involving novel hormonal agents for CRPC.

Main Methods:

  • Review of recent advances in understanding AR signaling pathways.
  • Analysis of completed and ongoing clinical trials for novel hormonal agents.
  • Focus on abiraterone acetate and enzalutamide (MDV3100) efficacy and mechanisms.

Main Results:

  • Continued AR signaling is a key mechanism in CRPC development.
  • Novel hormonal agents like abiraterone acetate and enzalutamide show promise in targeting AR signaling.
  • Clinical trials are evaluating the efficacy of these agents in patients with CRPC.

Conclusions:

  • Targeting AR signaling represents a promising therapeutic strategy for CRPC.
  • Abiraterone acetate and enzalutamide are key agents in the development of new CRPC treatments.
  • Ongoing research and clinical trials are essential for advancing CRPC management.

More Related Videos

Serum and Plasma Copy Number Detection Using Real-time PCR09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...